“Research and development keeps our companies on
the cutting edge of global competitiveness. R&D brought us smart phones,
airplanes, vaccines, hybrid cars, the artificial hip and much more,” the
employees wrote. “U.S. companies employ high-skilled, high-wage workers across
America that depend on the R&D tax credit for maintaining the nation’s
leadership in biotechnology, manufacturing, technology, and other business
sectors in the U.S. If the credit
expires on December 31, it will place America’s innovation economy at risk.”
The U.S. House is scheduled to vote on a tax
extenders package today that would extend the R&D tax credit for one year,
but the credit’s future remains terribly uncertain.
While R&D is part of American DNA, it is not
something that comes cheap. R&D is expensive, and it takes planning to
bring those ideas to the marketplace. Our ability to pay for R&D, to map
out the future of the products it creates, and to keep those Americans involved
in one of our most important enterprises are threatened by congressional
inaction over the R&D tax credit.
It’s important to remember that United States isn’t
the only nation that gives R&D incentives. While Congress is slow to renew
the credit, other nations are not. When
the R&D Credit was first created, the U.S. had the distinction of providing
the most generous tax treatment for research among all OECD nations. Today,
that is not the case because the credit has been whittled away over the years
due to our global competitors such as Canada, China, Japan and others that
offer more aggressive R&D incentives. In fact, the U.S. has fallen out of
the top 10 globally when measuring government incentives for private sector
R&D and now measures 17th.